SCHEDULE: Goldman Sachs Discloses 5.6% Stake in SpringWorks
Beneficial Ownership Disclosure
The Goldman Sachs Group and its subsidiary Goldman Sachs & Co. LLC have disclosed a 5.6% beneficial ownership stake in SpringWorks Therapeutics, Inc.
Summary
- The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC have jointly filed a Schedule 13G, indicating beneficial ownership in SpringWorks Therapeutics, Inc.
- The reporting entities collectively beneficially own 4,234,033.35 shares of SpringWorks Therapeutics, Inc. Common Stock.
- This ownership represents 5.6% of the outstanding class of securities.
- The shares are primarily held with shared voting power (4,233,899.35 shares) and shared dispositive power (4,234,021.35 shares).
- The filing states that the securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 6
Explanation: The sentiment is moderately positive. While a Schedule 13G is a passive filing, the disclosure of a significant stake by a reputable institution like Goldman Sachs can be viewed favorably by the market, suggesting a vote of confidence in the issuer without implying active intervention.
Positives
- A significant institutional investor like Goldman Sachs holding a 5.6% stake may signal confidence in SpringWorks Therapeutics, Inc.'s long-term prospects.
- The acquisition of shares in the ordinary course of business suggests a standard investment strategy rather than an activist intent.
Negatives
- The filing does not contain any negative information regarding SpringWorks Therapeutics, Inc.'s operations or financial performance.
Risks
- The filing itself does not detail specific risks related to SpringWorks Therapeutics, Inc.'s business, but rather the nature of Goldman Sachs's passive investment.
- The investment is a passive stake, meaning Goldman Sachs does not intend to influence control, which limits potential strategic benefits from their involvement beyond capital.
Future Outlook
The filing is a disclosure of beneficial ownership and does not provide any forward-looking statements or guidance regarding SpringWorks Therapeutics, Inc.'s future performance or outlook.
Industry Context
This filing indicates a significant passive investment by a major financial institution in a biotechnology company, which is a common occurrence in the sector as institutional investors seek exposure to growth opportunities in life sciences.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney Update | The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC updated their Power of Attorney, effective July 16, 2025, authorizing specific individuals to execute SEC filings. This new Power of Attorney supersedes previous versions from July 29, 2024, and October 1, 2024. | 2025-07-16 | This is an internal administrative update for the reporting entities (Goldman Sachs) to facilitate SEC filings and does not directly impact SpringWorks Therapeutics, Inc.'s corporate governance. |
Stakeholder Impact
- Shareholders: The disclosure of a significant institutional investor holding a stake may increase investor confidence and potentially attract further institutional interest.
- Employees, Customers, Suppliers, Creditors: No direct impact is indicated by this passive ownership filing.
Key Dates
| Date | Description |
|---|---|
| 2024-07-29 | Previous Power of Attorney granted by The Goldman Sachs Group, Inc. was superseded. |
| 2024-10-01 | Previous Power of Attorney granted by Goldman Sachs & Co. LLC was superseded. |
| 2025-06-30 | Date of event which required the filing of this statement. |
| 2025-07-16 | Date new Power of Attorney was signed by Goldman Sachs & Co. LLC and The Goldman Sachs Group, Inc. |
| 2025-07-17 | Date of filing of the Schedule 13G. |
| 2026-07-16 | Expiration date of the current Power of Attorney. |
Recommendation
holdThe filing indicates a significant passive stake by Goldman Sachs, which can be seen as a positive signal of institutional confidence in SpringWorks Therapeutics. However, as a Schedule 13G, it does not provide new operational or financial performance data for the issuer, nor does it suggest any active strategic involvement from Goldman Sachs. Therefore, while the institutional backing is noteworthy, it doesn't fundamentally alter the investment thesis based solely on this filing, warranting a 'hold' recommendation for existing investors and further due diligence for potential new investors.
Keywords
SpringWorks Therapeutics, Goldman Sachs, Institutional Ownership, Biotechnology, Pharmaceuticals, Investment, Common Stock, SEC Filing, Schedule 13G
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.